Triple Receptor Agonist · Injectable
Retatrutide Injection
The world's most powerful triple-agonist peptide targeting GLP-1, GIP, and Glucagon receptors simultaneously for superior metabolic regulation.
Next-Gen Metabolic Health
CYNAPEPTDiscover the New You
UAE precision. Swiss expertise. American technology. Redefining global standards in metabolic health.
Who We Are
UAE-Based Pharmaceutical Innovator
Redefining Global Standards
CYNAPEPT is a UAE-based pharmaceutical leader that unites Swiss precision engineering with cutting-edge American technology to deliver next-generation metabolic health solutions.
Our objective is clear: to become one of the world's most trusted innovators in obesity medicine — setting the benchmark for efficacy, safety, and patient outcomes across the globe.
🇦🇪UAE Headquartered
🇨🇭Swiss Standards
🇺🇸US Technology
UAE
Headquarters & Strategic Hub
3+
Premium Products Available
99.9%
Purity Guarantee Per Batch
GMP
Certified Manufacturing
Our Vision
“To become one of the world's most trusted pharmaceutical innovators in metabolic health, setting the benchmark for efficacy and safety.”
Our Mission
Scientific Innovation
Pushing the boundaries of metabolic medicine with cutting-edge research.
Premium Quality Standards
Rigorous quality controls and GMP certified production.
Global Manufacturing Excellence
Advanced facilities designed for scale and temperature-sensitive integrity.
Patient-Centric Approach
Delivering therapies optimized for compliance and premium patient experiences.
Therapeutic Focus
Targeting Core Metabolic Diseases
Our scientific research and product formulations address the most pressing global health challenges of our time.
Metabolic Health
Supporting overall physiological pathways and cellular health.
Weight Management
Precision therapeutic intervention for sustained weight regulation.
Obesity
Setting new standards in obesity medicine through advanced triple receptor agonists.
Type 2 Diabetes
Validated glycemic control therapies optimizing pancreatic function.
Cardiometabolic
Addressing complex heart and metabolic syndromes collectively.
Our Product Portfolio
Next-generation metabolic health therapies — precision-engineered for maximum efficacy, safety, and patient compliance.
Triple Receptor Agonist · Lyophilized
Retatrutide Powder
High-purity lyophilized Retatrutide formulation for extended stability — ideal for research facilities and clinical applications.
Dual Receptor Agonist · Injectable
Tirzepatide Injection
Dual-targeted GLP-1 and GIP receptor agonist delivering clinically validated glycemic control and significant weight reduction.
Dual Receptor Agonist · Lyophilized
Tirzepatide Powder
Premium-grade lyophilized Tirzepatide with guaranteed 99.9% purity — the clinical research standard.
Oral GLP-1 Receptor Agonist · Non-peptide
Orforglipron Tablets
Next-generation oral non-peptide GLP-1 receptor agonist — effective metabolic therapy without injections.
Product Comparison
Evaluate mechanisms, administration methods, and patient profile targets across our formulations.
| Feature | Retatrutide | Tirzepatide | Orforglipron |
|---|---|---|---|
| Mechanism | Triple Agonist (GLP-1 / GIP / GCG) | Dual Agonist (GLP-1 / GIP) | Oral Agonist (GLP-1) |
| Administration | Weekly Injection | Weekly Injection | Daily Tablet |
| Primary Target | Maximum Weight Reduction | Obesity & T2D Control | Convenient Weight Mgmt |
| Patient Profile | Treatment Resistant Cases | Mainline Clinical Patients | Preference for Oral Therapy |
GMPCertified
Manufacturing Excellence
Built on Precision,
Delivered with Integrity
GMP-Certified Manufacturing
Every CYNAPEPT product is manufactured in GMP-certified facilities, adhering to the strictest international pharmaceutical standards across all production stages.
Cold Chain Integrity
Our dedicated cold-chain logistics ensure temperature-sensitive peptides maintain full potency and stability from production through final delivery.
Multi-Stage Quality Assurance
Each batch undergoes comprehensive HPLC analysis, sterility testing, and independent third-party verification to guarantee ≥ 99.9% purity.
Scalable Production Capacity
Our infrastructure is engineered for global-scale output, ensuring consistent availability and rapid response to growing international demand.
Product Pipeline & Roadmap
Our development roadmap outlines our transition from flagship metabolic therapies to cardiovascular development.
01
Current Flagship
Retatrutide
Triple-receptor agonist actively leading weight-regulation outcomes.
02
In Market
Tirzepatide
Dual GLP-1/GIP agonist with extensive clinical validation and distribution.
03
Rollout Phase
Orforglipron
High-compliance daily tablet making obesity treatment injection-free.
04
2026 Development
Cardio Portfolio
Broadening therapeutic reach into cardiovascular and lipid health.
Why Choose CYNAPEPT
The CYNAPEPT Advantage
UAE Strategic Hub
Headquartered in the UAE — at the crossroads of global trade routes, providing unparalleled access to international markets.
Swiss Expertise
Precision engineering and pharmaceutical heritage from Swiss manufacturing standards applied to every product we produce.
American Technology
Cutting-edge US research and development — from advanced synthesis to state-of-the-art quality control systems.
GMP Quality Standards
Full adherence to international Good Manufacturing Practice standards, ensuring product safety and regulatory compliance.
Premium Approach
Modern pharmaceutical design focused on patient convenience, compliance, and optimal therapeutic outcomes.
Global Partnerships
An expansive and growing network of international medical partners, distributors, and research institutions.
Global Expansion
A Vision Without
Borders
CYNAPEPT is executing a structured three-phase global expansion strategy, delivering trusted metabolic health solutions to patients worldwide.
01Active Now
Phase 1
Middle East & CIS
Establishing our presence in the UAE and expanding across the Middle East, Russia, and the CIS region with premium metabolic therapies.
United Arab EmiratesSaudi ArabiaRussiaKazakhstanAzerbaijan
02Coming Soon
Phase 2
Europe & Asia
Strategic market entry into European and Asian markets, partnering with established medical distributors and clinical networks.
GermanyFranceTurkeyIndiaSingapore
032026+
Phase 3
Global Network
Comprehensive worldwide distribution infrastructure — delivering CYNAPEPT solutions to patients across every inhabited continent.
AmericasAfricaOceaniaSoutheast AsiaRest of World
Get In Touch
Let's Advance Health Together
Whether you are a medical professional, distributor, or institutional partner — our team is ready to support you with dedicated expertise.